Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Pharmaceutical company receives development milestone payment in clinical trial
May 26th, 2005
Maxim Pharmaceuticals, Inc., (MAXM) reported that it achieved a $1.0 million development milestone under an agreement with Myriad Genetics. The milestone is based on the dosing of the first patient in a phase 1 clinical program designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors. "We are very pleased with Myriad's progress in the MPC-6827 program and look forward to the phase 1 study results," stated Larry G. Stambaugh, Maxim's chairman and chief executive officer. Stambaugh added, "In the meantime we are continuing our efforts to advance other anticancer compounds into...
Source: Women's Health Weekly (2005-05-26)
|
